The ColaLife panel contributionConsultation on transforming healthcare deliveryANDi, Addis Ababa, January 2015 Simon Berry

ColaLife is a charity registered in the UKCharity number: 1142516

• Small, independent and catalytic• Focus on saving children’s lives• Looking for global impact through

• Innovation• Generating robust evidence• Sharing findings and learning• Influencing healthcare strategies

• No commercial interest

2009 2010 2011 2012 20131985What is ColaLife and who am I?

The scope of our work

What happened

Our starting point

2

4

The effects

5

1

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

6

What we did

3

The scope of our work

What happened

Our starting point

The effects

1

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

What we did

2 3

4 5 6

The scope of our work

What happened

Our starting point

The effects

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

What we did

2 3

4 5 6

1

Coca-Cola gets to most places, life-saving medicines don’t

Under 5 mortality is unacceptably high…

…when compared with more developed countries

Diarrhoea is the second biggest killer

2

Diarrhoea

The scope of our work

What happened

Our starting point

The effects

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

What we did

2 3

4 5 6

1

Dec 2011

The trial timeline

Mimicking Coca-Cola – creating a product people WANT

What we learnt

Litre sachets are too big

Measuring water was an issue

Willingness to pay

Preferred branding

3

Kit Yamoyo• Attractive

• Affordable

• Packaging is also:

• A measuring device for

the water

• A mixing device

• A storage device (the

soap tray is a lid)

• A cup

• And can be re-used

3

Mimicking Coca-Cola – Community-based marketing

3

The scope of our work

What happened

Our starting point

The effects

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

What we did

2 3

4 5 6

1

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

WholesaleK3.10

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

Assembly

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

Manufacture

Assembly

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

Manufacture

Assembly

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

Manufacture

Assembly

Distribution

WholesaleK3.10

RetailK3.70

CustomerK5.00

4

Demand PULLED the Kit Yamoyo into rural communities

The scope of our work

What happened

Our starting point

The effects

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

What we did

2 3

4 5 6

1

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.

60%Only 60% of mothers mixed ORS correctly when given 1 litre sachets.

0Nobody sold ORS or Zinc in the private sector.

Stock-outs in the public sector were common.

<1%of children received the correct treatment for diarrhoea

7.3kmWas the average distance to ORS.

>26kkits sold into the two remote rural trial areas in 12 months.

45%of children in trial areas received ORS/Zinc. Up from a baseline of <1%. Comparator sites stayed at <1%.

2.4kmThe distance to ORS/Zinc in the trial areas was reduced by two-thirds from 7.3km to 2.4km.

93%of Kit Yamoyo users mixed ORS correctly. Only 60% do when given 1 litre sachets.

The scope of our work

What happened

Our starting point

The effects

The ColaLife contribution

Consultation on transforming healthcare delivery

ANDi, Addis Ababa, January 2015

Recommendations

What we did

2 3

4 5 6

1

6

Don’t ignore EXISTING private sector supply chains in your strategy to distribute over the counter medicines

Focus on what you know people WANT not on what you

think they NEED

6

Get co-packaged ORS and Zinc on the essential

medicines list

6

Under-5 children have died from dehydration caused by diarrhoeain the time it took to give this presentation

colalife.orgcolalife.org/blog